SCHEMBL1198087

SCHEMBL1198087

CCOC(=O)c1cnn(-c2nc(-c3ccc(Cl)s3)cs2)c1C(F)(F)F

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.73
HPGD P15428 7/20 0.73
ALDH1A1 P00352 6/20 0.73
MEN1 O00255 6/20 0.73
KMT2A Q03164 6/20 0.73
L3MBTL1 Q9Y468 4/20 0.73
MAPT P10636 4/20 0.73
GAA P10253 2/20 0.73
TDP1 Q9NUW8 1/20 0.73
CYP1A2 P05177 2/20 0.72
CYP2C9 P11712 2/20 0.72
CYP2C19 P33261 2/20 0.72
POLB P06746 1/20 0.69
RAB9A P51151 4/20 0.54
NPC1 O15118 3/20 0.54
CRHBP P24387 1/20 0.52
MC4R P32245 1/20 0.52
CRHR2 Q13324 1/20 0.52
ATM Q13315 1/20 0.52
GUCY1A1 Q02108 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875524 0.88 HPGD (0.56) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL1198028 0.85 MEN1 (0.73) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL1198425 0.84 KDM4E (0.78) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL1198615 0.83 KDM4E (0.83) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL1198850 0.83 KDM4E (0.84) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL1198683 0.81 KDM4E (0.67) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL1198891 0.80 KDM4E (0.85) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL7346602 0.80 KDM4E (0.85) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL1198475 0.80 KDM4E (0.80) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL1197979 0.80 KDM4E (0.71) KDM4EHPGDALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KDM4E 1877/4885HPGD 74/4885ALDH1A1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.